Cargando…

Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate

BACKGROUND: To identify retinal changes using spectral-domain optical coherence tomography (SD-OCT) and ultra-widefield images in eyes with primary vitreoretinal lymphoma (PVRL) during intravitreal methotrexate (MTX) treatment.  METHODS: This study retrospectively reviewed 111 eyes of 58 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tingting, Gu, Junxiang, Liu, Shixue, Chang, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487031/
https://www.ncbi.nlm.nih.gov/pubmed/36127675
http://dx.doi.org/10.1186/s12886-022-02604-7
_version_ 1784792406676209664
author Jiang, Tingting
Gu, Junxiang
Liu, Shixue
Chang, Qing
author_facet Jiang, Tingting
Gu, Junxiang
Liu, Shixue
Chang, Qing
author_sort Jiang, Tingting
collection PubMed
description BACKGROUND: To identify retinal changes using spectral-domain optical coherence tomography (SD-OCT) and ultra-widefield images in eyes with primary vitreoretinal lymphoma (PVRL) during intravitreal methotrexate (MTX) treatment.  METHODS: This study retrospectively reviewed 111 eyes of 58 patients with vitreous cytology-proven confirmed PVRL, who received intravitreal injections of MTX. RESULTS: At the initial visit, the OCT manifestations included vitreous cells (105 eyes, 94.6%), intraretinal infiltration (44 eyes,39.6%), subretinal infiltration (45 eyes, 40.5%,), retinal pigment epithelium (RPE) abnormalities (66 eyes, 59.5%), disruption of the ellipsoid zone (58 eyes, 52.3%), subretinal fluid (4 eyes, 3.6%), RPE detachment (PED) (28 eyes, 25.2%), epiretinal membrane (ERM) (8 eyes, 7.2%), macular edema (10 eyes, 9%). After therapy, tumor regression was achieved in all eyes. Between the initial presentation and regression, the vitreous cells (94.6% vs. 0%, P < 0.001), intraretinal infiltration (39.6% vs. 0%, P < 0.001), RPE abnormalities (59.5% vs.19.8%, P < 0.001), PED (25.2% vs.0%, P < 0.001), and subretinal infiltration (40.5%vs.16.2%, P < 0.001) were significantly reduced. The fundus photography findings all improved after therapy. The mean Logarithm of the Minimum Angle of Resolution (logMAR) for the best corrected visual acuity (BCVA) at presentation was 0.79 ± 0.81 (range, 0–2.9), which improved to 0.70 ± 0.97 (range, 0–2.9, P = 0.01) at the final visit. CONCLUSIONS: SD-OCT combined with ultra-widefield imaging, which can reflect retinal changes, are valuable tools for monitoring the effect of PVRL treatment.
format Online
Article
Text
id pubmed-9487031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94870312022-09-21 Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate Jiang, Tingting Gu, Junxiang Liu, Shixue Chang, Qing BMC Ophthalmol Research BACKGROUND: To identify retinal changes using spectral-domain optical coherence tomography (SD-OCT) and ultra-widefield images in eyes with primary vitreoretinal lymphoma (PVRL) during intravitreal methotrexate (MTX) treatment.  METHODS: This study retrospectively reviewed 111 eyes of 58 patients with vitreous cytology-proven confirmed PVRL, who received intravitreal injections of MTX. RESULTS: At the initial visit, the OCT manifestations included vitreous cells (105 eyes, 94.6%), intraretinal infiltration (44 eyes,39.6%), subretinal infiltration (45 eyes, 40.5%,), retinal pigment epithelium (RPE) abnormalities (66 eyes, 59.5%), disruption of the ellipsoid zone (58 eyes, 52.3%), subretinal fluid (4 eyes, 3.6%), RPE detachment (PED) (28 eyes, 25.2%), epiretinal membrane (ERM) (8 eyes, 7.2%), macular edema (10 eyes, 9%). After therapy, tumor regression was achieved in all eyes. Between the initial presentation and regression, the vitreous cells (94.6% vs. 0%, P < 0.001), intraretinal infiltration (39.6% vs. 0%, P < 0.001), RPE abnormalities (59.5% vs.19.8%, P < 0.001), PED (25.2% vs.0%, P < 0.001), and subretinal infiltration (40.5%vs.16.2%, P < 0.001) were significantly reduced. The fundus photography findings all improved after therapy. The mean Logarithm of the Minimum Angle of Resolution (logMAR) for the best corrected visual acuity (BCVA) at presentation was 0.79 ± 0.81 (range, 0–2.9), which improved to 0.70 ± 0.97 (range, 0–2.9, P = 0.01) at the final visit. CONCLUSIONS: SD-OCT combined with ultra-widefield imaging, which can reflect retinal changes, are valuable tools for monitoring the effect of PVRL treatment. BioMed Central 2022-09-20 /pmc/articles/PMC9487031/ /pubmed/36127675 http://dx.doi.org/10.1186/s12886-022-02604-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jiang, Tingting
Gu, Junxiang
Liu, Shixue
Chang, Qing
Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate
title Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate
title_full Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate
title_fullStr Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate
title_full_unstemmed Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate
title_short Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate
title_sort retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487031/
https://www.ncbi.nlm.nih.gov/pubmed/36127675
http://dx.doi.org/10.1186/s12886-022-02604-7
work_keys_str_mv AT jiangtingting retinalchangesofprimaryvitreoretinallymphomaafterintravitrealmethotrexate
AT gujunxiang retinalchangesofprimaryvitreoretinallymphomaafterintravitrealmethotrexate
AT liushixue retinalchangesofprimaryvitreoretinallymphomaafterintravitrealmethotrexate
AT changqing retinalchangesofprimaryvitreoretinallymphomaafterintravitrealmethotrexate